Literature DB >> 18055675

Pulmonary artery hypertension in formerly premature infants with bronchopulmonary dysplasia: clinical features and outcomes in the surfactant era.

Ekta Khemani1, Doff B McElhinney, Lawrence Rhein, Olyn Andrade, Ronald V Lacro, Kristin C Thomas, Mary P Mullen.   

Abstract

BACKGROUND: Although abnormal pulmonary vascular structure and function in preterm infants with bronchopulmonary dysplasia may predispose infants to pulmonary artery hypertension, little is known about the characteristics and outcomes of bronchopulmonary dysplasia-associated pulmonary artery hypertension in the surfactant era.
METHODS: We studied 42 premature infants (< 32 weeks of gestation) with bronchopulmonary dysplasia who were diagnosed as having pulmonary artery hypertension > or = 2 months after birth, between 1998 and 2006, at a median age of 4.8 months. Pulmonary artery hypertension was graded through echocardiography for all patients; 13 patients also underwent cardiac catheterization.
RESULTS: Eighteen (43%) of 42 patients had severe pulmonary artery hypertension (systemic or suprasystemic right ventricular pressure). Among 13 patients who underwent catheterization, the mean pulmonary artery pressure was 43 +/- 8 mmHg and the pulmonary vascular resistance index was 9.9 +/- 2.8 Wood units. In 12 patients, pulmonary artery pressure and pulmonary vascular resistance improved with 100% oxygen and 80 ppm inhaled nitric oxide but remained elevated. The pulmonary vascular resistance index decreased to 7.9 +/- 3.8 Wood units in 100% oxygen and to 6.4 +/- 3.1 Wood units with the addition of nitric oxide. Sixteen patients (38%) died during the follow-up period. Estimated survival rates were 64% +/- 8% at 6 months and 53% +/- 11% at 2 years after diagnosis of pulmonary artery hypertension. In multivariate analyses, severe pulmonary artery hypertension and small birth weight for gestational age were associated with worse survival rates. Among 26 survivors (median follow-up period: 9.8 months), pulmonary artery hypertension was improved, relative to its most severe level, in 24 patients (89%).
CONCLUSION: Premature infants with bronchopulmonary dysplasia and severe pulmonary artery hypertension are at high risk of death, particularly during the first 6 months after diagnosis of pulmonary artery hypertension.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18055675     DOI: 10.1542/peds.2007-0971

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  175 in total

Review 1.  Frontiers in pulmonary hypertension in infants and children with bronchopulmonary dysplasia.

Authors:  Joseph M Collaco; Lewis H Romer; Bridget D Stuart; John D Coulson; Allen D Everett; Edward E Lawson; Joel I Brenner; Anna T Brown; Melanie K Nies; Priya Sekar; Lawrence M Nogee; Sharon A McGrath-Morrow
Journal:  Pediatr Pulmonol       Date:  2012-07-06

2.  Increased Cardiac Output and Preserved Gas Exchange Despite Decreased Alveolar Surface Area in Rats Exposed to Neonatal Hyperoxia and Adult Hypoxia.

Authors:  Kara N Goss; Robert S Tepper; Tim Lahm; Shawn K Ahlfeld
Journal:  Am J Respir Cell Mol Biol       Date:  2015-12       Impact factor: 6.914

3.  Sildenafil Use in Children with Pulmonary Hypertension.

Authors:  Jennifer L Cohen; Shannon N Nees; Gerson A Valencia; Erika B Rosenzweig; Usha S Krishnan
Journal:  J Pediatr       Date:  2018-11-02       Impact factor: 4.406

4.  Excess soluble vascular endothelial growth factor receptor-1 in amniotic fluid impairs lung growth in rats: linking preeclampsia with bronchopulmonary dysplasia.

Authors:  Jen-Ruey Tang; S Ananth Karumanchi; Gregory Seedorf; Neil Markham; Steven H Abman
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2011-10-14       Impact factor: 5.464

5.  Prospective analysis of pulmonary hypertension in extremely low birth weight infants.

Authors:  Ramachandra Bhat; Ariel A Salas; Chris Foster; Waldemar A Carlo; Namasivayam Ambalavanan
Journal:  Pediatrics       Date:  2012-02-06       Impact factor: 7.124

Review 6.  Pharmacotherapy for pulmonary hypertension.

Authors:  Robin H Steinhorn
Journal:  Pediatr Clin North Am       Date:  2012-08-26       Impact factor: 3.278

7.  Bronchopulmonary Dysplasia: Executive Summary of a Workshop.

Authors:  Rosemary D Higgins; Alan H Jobe; Marion Koso-Thomas; Eduardo Bancalari; Rose M Viscardi; Tina V Hartert; Rita M Ryan; Suhas G Kallapur; Robin H Steinhorn; Girija G Konduri; Stephanie D Davis; Bernard Thebaud; Ronald I Clyman; Joseph M Collaco; Camilia R Martin; Jason C Woods; Neil N Finer; Tonse N K Raju
Journal:  J Pediatr       Date:  2018-03-16       Impact factor: 4.406

8.  Effects of long-term sildenafil treatment for pulmonary hypertension in infants with chronic lung disease.

Authors:  Peter M Mourani; Marci K Sontag; D Dunbar Ivy; Steven H Abman
Journal:  J Pediatr       Date:  2008-10-31       Impact factor: 4.406

Review 9.  An update on pharmacologic approaches to bronchopulmonary dysplasia.

Authors:  Sailaja Ghanta; Kristen Tropea Leeman; Helen Christou
Journal:  Semin Perinatol       Date:  2013-04       Impact factor: 3.300

Review 10.  Pulmonary hypertension in bronchopulmonary dysplasia.

Authors:  Sara K Berkelhamer; Karen K Mestan; Robin H Steinhorn
Journal:  Semin Perinatol       Date:  2013-04       Impact factor: 3.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.